Aliskiren Reduces Hepatic steatosis and Epididymal Fat Mass and Increases Skeletal Muscle Insulin Sensitivity in High-Fat Diet-Fed Mice

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Lee, Kuei Chuan ^a,b   Hsieh, Yun Cheng ^a,b   Yang, Ying Ying ^a,b   Chan, Che Chang ^a,b   Huang, Yi Hsiang ^a,b   Lin, Han Chieh ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; AMIDE; CARNITINE PALMITOYLTRANSFERASE; CYP4A14 PROTEIN, MOUSE; CYTOCHROME P450 FAMILY 4; FUMARIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B;

ADIPOSE TISSUE; ANATOMY AND HISTOLOGY; ANIMAL; DISEASE MODEL; DRUG EFFECTS; EPIDIDYMIS; INSULIN RESISTANCE; LIPID DIET; LIPID METABOLISM; LIVER; MALE; METABOLISM; MOUSE; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ADIPOSE TISSUE; AMIDES; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CARNITINE O-PALMITOYLTRANSFERASE; CYTOCHROME P450 FAMILY 4; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; EPIDIDYMIS; FUMARATES; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; MALE; MICE; MUSCLE, SKELETAL; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; PHOSPHORYLATION; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84953277546     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18899     Document Type: Article

References (38)

1. Farrell, G. C. & Larter, C. Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43, S99-S112 (2006).
2. Fassio, E., Alvarez, E., Dominguez, N., Landeira, G. & Longo, C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40, 820-826 (2004).
3. Ratziu, V. & Poynard, T. Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. Hepatology 44, 802-805 (2006).
4. Katan, M. B. Weight-loss diets for the prevention and treatment of obesity. N Engl J Med 360, 923-925 (2009).
5. Takahashi, N. et al. Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin. Cell Metab 6, 506-512 (2007).
6. Jayasooriya, A. P. et al. Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proc Natl Acad Sci USA 105, 6531-6536 (2008).
7. Nabeshima, Y., Tazuma, S., Kanno, K., Hyogo, H. & Chayama, K. Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol 50, 1226-1235 (2009).
8. Paschos, P. & Tziomalos, K. Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. World J Hepatol 4, 327-331 (2012).
9. Kishina, M. et al. Therapeutic effects of the direct renin inhibitor, aliskiren, on non-alcoholic steatohepatitis in fatty liver Shionogi ob/ob male mice. Hepatol Res 44, 888-896 (2014).
10. Lee, K. C. et al. Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet. PloS one 8, e77817 (2013).
11. Rinella, M. E. & Green, R. M. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 40, 47-51 (2004).
12. Habibi, J. et al. Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology 149, 5643-5653 (2008).
13. Lastra, G. et al. Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology 150, 2561-2568 (2009).
14. Kang, Y. S. et al. Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice. Nephrol Dial Transplant 26, 1194-1204 (2011).
15. Gandhi, S., Srinivasan, B. & Akarte, A. S. Aliskiren improves insulin resistance and ameliorates diabetic renal vascular complications in STZ-induced diabetic rats. J Renin Angiotensin Aldosterone Syst 14, 3-13 (2013).
16. Marchionne, E. M., Diamond-Stanic, M. K., Prasonnarong, M. & Henriksen, E. J. Chronic renin inhibition with aliskiren improves glucose tolerance, insulin sensitivity, and skeletal muscle glucose transport activity in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 302, R137-142 (2012).
17. Donnelly, K. L. et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115, 1343-1351 (2005).
18. Frantz, E. D., Penna-de-Carvalho, A., Batista Tde, M., Aguila, M. B. & Mandarim-de-Lacerda, C. A. Comparative effects of the reninangiotensin system blockers on nonalcoholic fatty liver disease and insulin resistance in C57BL/6 mice. Metabolic syndrome and related disorders 12, 191-201 (2014).
19. Vaidyanathan, S., Jarugula, V., Dieterich, H. A., Howard, D. & Dole, W. P. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet 47, 515-531 (2008).
20. Toulmond, S., Kwong, E. & Macdonald, D. inventors; Merck Canada Inc., assignee. Transdermally administered aliskiren. European patent EP2373306 A1. 2011Oct 12.
21. Vidal-Puig, A. et al. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J Clin Invest 97, 2553-2561 (1996).
22. Schadinger, S. E., Bucher, N. L., Schreiber, B. M. & Farmer, S. R. PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol Endocrinol Metab 288, E1195-1205 (2005).
23. Zhang, Y. L. et al. Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. J Biol Chem 281, 37603-37615 (2006).
24. Zhou, J. et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology 134, 556-567 (2008).
25. Kim, S. P. et al. Transcriptional activation of peroxisome proliferator-activated receptor-gamma requires activation of both protein kinase A and Akt during adipocyte differentiation. Biochem Biophys Res Commun 399, 55-59 (2010).
26. Prusty, D., Park, B. H., Davis, K. E. & Farmer, S. R. Activation of MEK/ERK signaling promotes adipogenesis by enhancing peroxisome proliferator-activated receptor gamma (PPARgamma ) and C/EBPalpha gene expression during the differentiation of 3T3-L1 preadipocytes. J Biol Chem 277, 46226-46232 (2002).
27. Herzig, S. et al. CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-gamma. Nature 426, 190-193 (2003).
28. Sozio, M. S., Lu, C., Zeng, Y., Liangpunsakul, S. & Crabb, D. W. Activated AMPK inhibits PPAR-{alpha} and PPAR-{gamma} transcriptional activity in hepatoma cells. Am J Physiol Gastrointest Liver Physiol 301, G739-747 (2011).
29. Minokoshi, Y. et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415, 339-343 (2002).
30. Pessin, J. E. & Saltiel, A. R. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 106, 165-169 (2000).
31. Stucchi, P., Cano, V., Ruiz-Gayo, M. & Fernandez-Alfonso, M. S. Aliskiren reduces body-weight gain, adiposity and plasma leptin during diet-induced obesity. British journal of pharmacology 158, 771-778 (2009).
32. Tontonoz, P., Hu, E. & Spiegelman, B. M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79, 1147-1156 (1994).
33. Kubota, N. et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Molecular cell 4, 597-609 (1999).
34. Guilherme, A., Virbasius, J. V., Puri, V. & Czech, M. P. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 9, 367-377 (2008).
35. Ferre, P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53 Suppl 1, S43-50 (2004).
36. Csibi, A., Communi, D., Müller, N. & Bottari, S. P. Angiotensin II Inhibits Insulin-Stimulated GLUT4 Translocation and Akt Activation through Tyrosine Nitration-Dependent Mechanisms. PloS one 5, e10070 (2010).
37. Stenbit, A. E. et al. GLUT4 heterozygous knockout mice develop muscle insulin resistance and diabetes. Nat Med 3, 1096-1101 (1997).
38. Lu, H. et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 118, 984-993 (2008).